reports
IBio Inc: 2 directors
Two Directors at IBio Inc bought 37,171 shares at between 2.019USD and 2.020USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
iBio Provides Status Update on its Continuing Litigation Against Fraun...
iBio Provides Status Update on its Continuing Litigation Against Fraunhofer NEW YORK, Dec. 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, announced today that the Second Complaint it filed in iBio’s litigation against the Fraunhofer organization – this time against Fraunhofer Gesellschaft (“FhG”), complaining that FhG had committed fraud against and was responsible for contractual breaches against iBio – was dismissed by the Delaware Chancery Court as untimely filed. The original Complaint filed against Fraunhofer USA, Inc. ...
iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmac...
iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is sponsored by Bio-Manguinhos/Fiocruz, a unit of the Brazilian Ministry of Health. Sancha Salgueiro, Ph.D., MBA, a well-known expert and business development executive focussed on plant-made protein technologies and produc...
iBio and CC-Pharming Hold First Design and Strategy Meeting
iBio and CC-Pharming Hold First Design and Strategy Meeting Texas Meeting Initiates Plan to Bring Economical, Plant-Derived Rituximab to China Market NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan Texas. The meeting initiates the first stage of the companies’ business collaboration and will include work on product, process, and facility design ...
iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance
iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that NYSE Regulation has accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) and has granted a plan period through December 6, 2019, subject to periodic review by the Exchange, including quarterly monitoring, for compliance with the initiatives outlined in the plan. If t...
iBio Establishes Strategic Commercial Relationship with CC-Pharming Lt...
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities for the Chinese biopharmaceutical market, utilizing iBio’s technology. The first product focus selected pursuant to the Master Joint Development Agreement executed between iBio and CC-Pharming will be a therapeutic antibody, with additional, mutually se...
iBio, Inc. Closes $16,000,000 Public Offering
iBio, Inc. Closes $16,000,000 Public Offering NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced that it has closed its previously announced underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 4,350,000 shares of Common Stock at $0.90 per share, (ii) 6,300 shares of Series A Convertible Preferred Stock, with a stated value o...
iBio, Inc. Prices $16,000,000 Public Offering
iBio, Inc. Prices $16,000,000 Public Offering NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 4,350,000 shares of Common Stock at $0.90 per share, (ii) 6,300 shares of Series A Convertible Preferred Stock, with a stated value of $1,000 per preferred sha...
iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split
iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that its previously announced 1-for-10 reverse stock split of common stock became effective today at 4:10 p.m. (Eastern Time) (the “Effective Time”). The Company’s common stock will continue to trade on the NYSE American under the symbol “IBIO” under a new CUSIP number: 451033 203. The Company’s common stock will begin trading on a split-adjusted basis when the market opens on June 11, 2018. At the Effectiv...
iBio, Inc. Reports on NYSE American Noncompliance Notice and Complianc...
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that on June 6, 2018, the Company received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards as set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”), which applies if a listed company has stockholders’ equity of less than $6,000,000 and has sustained losses from continu...
iBio and ONEWAY Diagnostica Develop New Products for Brazil
iBio and ONEWAY Diagnostica Develop New Products for Brazil NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced a joint product development, manufacturing and revenue sharing agreement with ONEWAY Diagnostica of Brazil for novel point of care diagnostic products initially focused on Zika and Chikungunya virus infections. iBio will provide antigen and antibody manufacturing for product prototype development, regulatory approval, commercial launch and ongoing commercial exploitation. ONEWAY Diagnostica will manage marketing, distribution and sales in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.